Total Payments
$82,377
2024 Payments
$4,692
Companies
94
Transactions
1,333
Medicare Patients
33,650
Medicare Billing
$6.8M
Payment Breakdown by Category
Other$41,873 (50.8%)
Food & Beverage$22,533 (27.4%)
Consulting$15,739 (19.1%)
Research$1,890 (2.3%)
Education$330.94 (0.4%)
Travel$11.60 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $40,448 | 14 | 49.1% |
| Food and Beverage | $22,533 | 1,289 | 27.4% |
| Consulting Fee | $15,739 | 11 | 19.1% |
| Unspecified | $1,890 | 2 | 2.3% |
| Honoraria | $1,425 | 2 | 1.7% |
| Education | $330.94 | 14 | 0.4% |
| Travel and Lodging | $11.60 | 1 | 0.0% |
Payments by Type
General
$80,487
1,331 transactions
Research
$1,890
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| SANOFI-AVENTIS U.S. LLC | $23,743 | 4 | $0 (2018) |
| Celgene Corporation | $23,486 | 76 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $10,126 | 44 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $3,896 | 134 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $2,128 | 147 | $0 (2024) |
| Pharmacyclics LLC, An AbbVie Company | $1,562 | 17 | $0 (2023) |
| Janssen Biotech, Inc. | $1,375 | 76 | $0 (2024) |
| Genentech USA, Inc. | $1,346 | 102 | $0 (2023) |
| Epizyme, Inc., | $1,268 | 2 | $0 (2021) |
| PFIZER INC. | $1,261 | 94 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,692 | 220 | PFIZER INC. ($374.84) |
| 2023 | $4,318 | 222 | Novartis Pharmaceuticals Corporation ($372.65) |
| 2022 | $9,484 | 145 | AstraZeneca Pharmaceuticals LP ($4,832) |
| 2021 | $4,473 | 68 | AstraZeneca Pharmaceuticals LP ($2,093) |
| 2020 | $1,296 | 74 | E.R. Squibb & Sons, L.L.C. ($255.77) |
| 2019 | $18,427 | 202 | Celgene Corporation ($13,036) |
| 2018 | $12,979 | 181 | Celgene Corporation ($6,495) |
| 2017 | $26,708 | 221 | SANOFI-AVENTIS U.S. LLC ($20,762) |
All Payment Transactions
1,333 individual payment records from CMS Open Payments — Page 1 of 54
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | ARRAY BIOPHARMA INC | LORBRENA (Drug), BRAFTOVI, MEKTOVI | Food and Beverage | In-kind items and services | $24.94 | General |
| Category: ONCOLOGY | ||||||
| 12/20/2024 | SOBI, INC | VONJO (Drug) | Food and Beverage | In-kind items and services | $49.89 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/20/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $25.36 | General |
| Category: Oncology | ||||||
| 12/19/2024 | Geron Corporation | RYTELO (Drug) | Food and Beverage | In-kind items and services | $20.54 | General |
| Category: MYELODYSPLASTIC SYNDROME | ||||||
| 12/18/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $16.34 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 12/17/2024 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $13.66 | General |
| Category: Oncology | ||||||
| 12/11/2024 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug) | Food and Beverage | In-kind items and services | $29.13 | General |
| Category: Oncology | ||||||
| 12/10/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $24.51 | General |
| Category: Oncology | ||||||
| 12/10/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $14.27 | General |
| Category: Oncology | ||||||
| 12/09/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $20.40 | General |
| Category: Oncology | ||||||
| 12/05/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $23.46 | General |
| Category: ONCOLOGY | ||||||
| 12/05/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug), Somatuline Depot | Food and Beverage | In-kind items and services | $21.23 | General |
| Category: Oncology | ||||||
| 12/04/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $22.52 | General |
| 12/03/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Food and Beverage | In-kind items and services | $27.72 | General |
| Category: Oncology | ||||||
| 12/03/2024 | Tempus AI, Inc | XT CDX (Device) | Food and Beverage | In-kind items and services | $20.26 | General |
| Category: NONE | ||||||
| 12/03/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $13.93 | General |
| Category: Oncology | ||||||
| 11/21/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $27.70 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 11/21/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $23.66 | General |
| Category: Oncology | ||||||
| 11/21/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $22.66 | General |
| Category: Oncology | ||||||
| 11/19/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $16.23 | General |
| Category: Oncology | ||||||
| 11/18/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Food and Beverage | In-kind items and services | $27.74 | General |
| Category: DESMOID TUMORS | ||||||
| 11/18/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $13.56 | General |
| Category: Oncology | ||||||
| 11/14/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $17.55 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 11/08/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $49.72 | General |
| Category: Oncology | ||||||
| 11/08/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $22.04 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| CC-5013-NHL-007 | Celgene Corporation | $1,240 | 1 |
| CC-5013-NHL-007 - A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Placebo in Subjects With Relapsed/Refractory Indolent Lympho | Celgene Corporation | $650.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 55 | 5,405 | 181,554 | $4.9M | $1.3M |
| 2022 | 79 | 7,927 | 185,084 | $4.9M | $1.3M |
| 2021 | 87 | 9,806 | 176,156 | $5.8M | $1.6M |
| 2020 | 92 | 10,512 | 222,265 | $8.5M | $2.6M |
Total Patients
33,650
Total Services
765,059
Medicare Billing
$6.8M
Procedure Codes
313
All Medicare Procedures & Services
313 procedure records from CMS Medicare Utilization — Page 1 of 13
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 113 | 17,460 | $890,460 | $322,030 | 36.2% |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 2023 | 11 | 6,782 | $732,456 | $243,085 | 33.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 720 | 1,705 | $577,995 | $158,799 | 27.5% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2023 | 75 | 22,590 | $519,570 | $132,266 | 25.5% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 72 | 80 | $296,480 | $86,959 | 29.3% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 87 | 416 | $157,248 | $40,375 | 25.7% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 74 | 82 | $55,760 | $32,851 | 58.9% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 166 | 569 | $107,541 | $26,747 | 24.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 151 | 151 | $88,335 | $24,691 | 28.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 943 | 2,773 | $24,957 | $23,277 | 93.3% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 949 | 2,994 | $86,826 | $22,736 | 26.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 102 | 163 | $77,262 | $22,116 | 28.6% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 28 | 15,730 | $78,650 | $21,617 | 27.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 316 | 1,611 | $111,159 | $16,742 | 15.1% |
| J9395 | Injection, fulvestrant, 25 mg | Office | 2023 | 15 | 1,900 | $250,800 | $16,293 | 6.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 152 | 221 | $52,819 | $13,532 | 25.6% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 32 | 33,150 | $132,600 | $13,169 | 9.9% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 50 | 55 | $30,250 | $9,245 | 30.6% |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | Office | 2023 | 13 | 59 | $37,583 | $7,542 | 20.1% |
| J1756 | Injection, iron sucrose, 1 mg | Office | 2023 | 72 | 45,800 | $229,000 | $7,334 | 3.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 62 | 62 | $28,086 | $7,048 | 25.1% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 101 | 590 | $35,990 | $6,869 | 19.1% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 74 | 296 | $24,864 | $6,376 | 25.6% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 23 | 109 | $19,402 | $5,295 | 27.3% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 40 | 239 | $18,881 | $5,108 | 27.1% |
About Dr. David Wright, MD
Dr. David Wright, MD is a Hematology healthcare provider based in Tampa, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/24/2006. The National Provider Identifier (NPI) number assigned to this provider is 1699745638.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Wright, MD has received a total of $82,377 in payments from pharmaceutical and medical device companies, with $4,692 received in 2024. These payments were reported across 1,333 transactions from 94 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($40,448).
As a Medicare-enrolled provider, Wright has provided services to 33,650 Medicare beneficiaries, totaling 765,059 services with total Medicare billing of $6.8M. Data is available for 4 years (2020–2023), covering 313 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology
- Other Specialties Hematology & Oncology, Medical Oncology
- Location Tampa, FL
- Active Since 01/24/2006
- Last Updated 09/02/2022
- Taxonomy Code 207RH0000X
- Entity Type Individual
- NPI Number 1699745638
Products in Payments
- Revlimid (Drug) $22,836
- LEMTRADA (Drug) $20,750
- LYNPARZA (Drug) $4,217
- CALQUENCE (Drug) $3,787
- TAXOTERE (Drug) $2,977
- ABECMA (Biological) $1,976
- OPDIVO (Biological) $1,578
- Imbruvica (Drug) $1,275
- TAZVERIK (Drug) $1,268
- KISQALI (Drug) $844.66
- KEYTRUDA (Biological) $591.64
- IMBRUVICA (Drug) $589.09
- TECENTRIQ (Biological) $527.98
- VERZENIO (Drug) $513.61
- Lenvima (Drug) $498.83
- REBLOZYL (Biological) $401.88
- IBRANCE (Drug) $393.88
- ERLEADA (Drug) $378.49
- DARZALEX (Biological) $371.21
- JAKAFI (Drug) $319.38
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology Doctors in Tampa
Rami Komrokji, M.d, M.D
Hematology — Payments: $850,782
Hematology $850,782
Dr. Julia Cogburn, M.d, M.D
Hematology — Payments: $133,076
Hematology $133,076
Dr. Robert Weaver, Md, MD
Hematology — Payments: $110,649
Hematology $110,649
Alan List, Md, MD
Hematology — Payments: $94,305
Hematology $94,305
Lubomir Sokol, Md, MD
Hematology — Payments: $27,903
Hematology $27,903
Dr. Hafeez Chatoor, M.d, M.D
Hematology — Payments: $27,426
Hematology $27,426